{"organizations": [], "uuid": "1bee0b62383661c7fb6229e95039696ce69ea3a1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/", "section_title": "Business &amp; Financial News, U.S &amp; International Breaking News | Reuters", "url": "https://www.reuters.com/article/us-acorda-m-a/acorda-therapeutics-exploring-sale-wsj-idUSKBN1EU20A", "country": "US", "domain_rank": 408, "title": "Acorda Therapeutics exploring sale: WSJ", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.002, "site_type": "news", "published": "2018-01-06T05:15:00.000+02:00", "replies_count": 0, "uuid": "1bee0b62383661c7fb6229e95039696ce69ea3a1"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/us-acorda-m-a/acorda-therapeutics-exploring-sale-wsj-idUSKBN1EU20A", "ord_in_thread": 0, "title": "Acorda Therapeutics exploring sale: WSJ", "locations": [], "entities": {"persons": [{"name": "manas mishra", "sentiment": "none"}, {"name": "maju samuel", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "ardsley", "sentiment": "none"}, {"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "acorda therapeutics", "sentiment": "negative"}, {"name": "wsj", "sentiment": "negative"}, {"name": "acorda", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "(Reuters) - Acorda Therapeutics ( ACOR.O ) is exploring a sale of the company, the Wall Street Journal reported, citing people familiar with the matter.\nShares of the company closed up nearly 12 percent at $23.55 on Friday.\nThe Ardsley, New York-based company, which has a market value of about $980 million, may not move forward with any formal action as the proceedings were at an early stage, the WSJ report said. ( on.wsj.com/2F32ebR )\nAcorda was not immediately available for comment.\nThe U.S. drugmaker’s investors in August had called for the company to explore a sale, after a judge in March struck down key patents of its MS drug Ampyra, which accounts for most of its revenue.\nThe company also recently discontinued the development of its Parkinson’s drug after reports of death.\nReporting by Manas Mishra in Bengaluru; Editing by Maju Samuel\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html", "http://on.wsj.com/2F32ebR"], "published": "2018-01-06T05:15:00.000+02:00", "crawled": "2018-01-06T11:37:38.002+02:00", "highlightTitle": ""}